Advisory company focused on the development of personalized medicine launched

Elixior Limited, the advisory company focused on the development and growth of innovative personalized medicine businesses, announced today its launch by the founder and former CEO of Curidium, Dr Anne Bruinvels.

Elixior's business activities are aimed at: - Supporting the development and growth of personalized medicine businesses through the creation of partnerships and / or the sourcing of investments - Helping personalized medicine companies with the structuring of their corporate and commercial strategies - Conducting due diligence on personalized medicine ventures - Building a world-wide, personalized medicine knowledge-base to support cooperation between personalized medicine businesses and the growth of the sector.

Dr Anne Bruinvels, founder and CEO of Elixior, commented: "The field of personalized medicine is moving forward rapidly and it is Elixior's aim to help the development and commercialization of new innovations in this exciting area. Personalized medicine has the potential to treat patients more effectively and to make healthcare much more cost-effective over time. I look forward to working with small and big companies alike planning to move into or expand in this field."

Previously, Dr Anne Bruinvels founded Curidium, a personalized medicine company focused on improving the diagnosis and treatment of central nervous system disorders. She was Curidium's CEO for more than six years, during which she took the company public on the AIM of the London Stock Exchange.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients